Evidence map›Paper›PMID 40848089›Full record

ReviewCurrent topics in behavioral neurosciences2026

Acute Effects and Long-Term Neuropsychological Consequences of Classic Psychedelics Use.

Lukas Andreas Basedow, Thomas Günther Riemer

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current topics in behavioral neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Lukas Andreas BasedowDepartment of Psychology, Clinical Psychology and Psychotherapy, Philipps-Universität Marburg, Marburg, Germany. lukas.basedow@uni-marburg.de.
Thomas Günther RiemerCharité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Clinical Pharmacology and Toxicology, Campus Charité Mitte, Charité Universitätsmedizin Berlin, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psychedelics are gaining attention for their potential as therapeutic adjuncts for the treatment of psychological disorders. Additionally, the recreational use of these substances has been rising for the past years. In the context of a comprehensive analysis of potential harms induced by these substances, concerns regarding the cognitive and neuropsychological impact of their use remain. This chapter explores the acute, subacute, and long-term neuropsychological consequences of psychedelic use. Studies show that neuropsychological performance, especially attention and working memory, is reduced under the influence of a psychedelic. While not harmful in itself, this effect poses potential risks when combined with high-risk environments, such as road traffic. While these acute impairments seem to disappear on the day after psychedelic use, there is limited evidence that some impairments in executive functioning can persist for up to 24 h. Thus, caution is not only warranted during psychedelic use but also for the following day. In contrast, psychedelics do not seem to induce persistent changes in neuropsychological performance through repeated use, indicating no direct neuropsychological harms. However, further research is required to clarify the differential effects of various psychedelic substances and to assess the impact of chronic use across different contexts.

Indexed as

AttentionCognitionExecutive FunctionHallucinogensHumansMemory, Short-TermNeuropsychological TestsHallucinogensCognitionHallucinogensHarm ReductionNeuropsychology

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.